Unlocking the full potential
of highly potent anticancer drugs
We aim to deliver the best anticancer treatments to patients by a simple subcutaneous injection.
Despite all the efforts in the fight against cancer, some tumors are still resistant to currently available treatments. Highly active pharmaceutical ingredients (HPAPI) are drugs 100 to 1000 times more active than traditional chemotherapies. Unfortunately, patients cannot benefit from HPAPIs as they are currently impossible to administer in their current form. Imescia’s unique technology allows a simple subcutaneous injection of HPAPI in the form of a novel polymer prodrug.
TECHNOLOGY
Imescia’s technology is the first capable of innocuous subcutaneous administration of irritant / vesicant anticancer HPAPI.
HPAPIs have not reached the patient due to three limitations:
- Their poor solubility makes them impossible to administer intravenously
- A pill cannot be made from them due to their poor oral bioavailability
- Their high activity comes at a cost of high toxicities that must be managed
Thanks to our extremely hydrophilic polymer, we can solubilize even the most insoluble small molecules. Our subcutaneous approach allows rapid and high bioavailability. The enhanced pharmacokinetics profile at an optimal dosing, below the toxicity level and above the therapeutic level, greatly decreases the toxicities of the HPAPI and unlocks their true therapeutic potential.
Imescia's technology addresses HPAPI limitations
Simple subcutaneous injection
Pharmacokinetics of different administration routes
Imescia’s subcutaneous long release enhances the efficacy of HPAPI
We are advancing in the preclinical development of our lead product IMA-01, based on a highly potent anticancer drug.
With IMA-01 we seek to address tumors with an important unmet medical need. Our simple-to-use subcutaneous administration approach will allow a better treatment efficacy with fewer toxicities and a simplified treatment for the patient as opposed to an intravenous infusion.
We are actively looking for partnership opportunities to adapt our technology to the best HPAPIs
Our prodrug polymer technology is a platform that can be adapted to a wide variety of small molecules, peptides and oligonucleotides.
Small molecules
Peptides
Oligonucleotides
We improve API solubility, stability, pharmacokinetics (enhanced half-life) and do not need to use additional surfactants or lipids for the formulation. This is particularly of interest for small molecules HPAPI, peptides and oligonucleotides. Get in touch with us to learn more about the technology.
ABOUT IMESCIA
Founded in 2019, Imescia is a spin-off company from the Institut Galien Paris-Sud, co-founded by Tanguy Boissenot CEO (Pharm.D., Ph.D.), Alexandre Bordat CTO (Ecole polytechnique, Ph.D.), Nicolas Tsapis (Ph.D., CNRS researcher), and Julien Nicolas (Ph.D., CNRS researcher). The company is the result of four years of fundamental research at the Institut Galien Paris-Sud. The team has the expertise in polymer synthesis and drug delivery systems.
OUR TEAM
Tanguy BOISSENOT
CEO co-founder
Pharm.D. Ph.D
Alexandre BORDAT
CTO co-founder
Ecole polytechnique - Ph.D
Nada IBRAHIM
Head of Chemistry
Ph.D.
Nicolas TSAPIS
Scientific advisor co-founder
Ph.D - DR CNRS
Physical-chemistry
Julien NICOLAS
Scientific advisor co-founder
Ph.D - DR CNRS
Polymer chemistry
CONTACT US
contact@imescia.com
5, rue Jean-Baptiste Clément
92290 Châtenay-Malabry
PARTNERS
MENTORING
GRANTS
ACADEMIC FUNDING
THANKS TO IPSEN FOR LABORATORY EQUIPMENT
Legal Notices
Imescia SAS is a French company with a capital of 10,000 EUR, registered with the Trade and Companies Registry of Nanterre under the number SIRET 85167068700025 with registered offices at 5, rue Jean-Baptiste Clément 92290 Châtenay-Malabry France.
Sites linked directly or indirectly to the imescia.com site are not under its control. Consequently, Imescia assumes no responsibility for the information published on these sites.
Image credits
Adapted from Servier Medical Art (SMART)
Web design by Laurent Muller
Hosting
1&1 IONOS SARL
SARL with capital of 100,000 EUR
RCS Sarreguemines B 431 303 775
SIRET 431 303 775 000 16
APE Code 6201Z
VAT number: FR 13 431 303 775
Headquarters: 7, place de la Gare – BP 70109 – 57200 Sarreguemines C
Publication Director: Alexandre Bordat – contact@imescia.com